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The increasing popularity and availability of electronic cigarettes 
(i.e., e-cigarettes) in many countries have promoted debate among 
health professionals as to what to recommend to their patients who 
might be struggling to stop smoking or asking about e-cigarettes. 
In the absence of  evidence-based guidelines for using e-cigarettes 
for smoking cessation, some health professionals have urged caution 
about recommending them due to the limited evidence of their safety 
and efficacy, while others have argued that e-cigarettes are obvi-
ously a better alternative to continued cigarette smoking and should 
be encouraged. The leadership of the International Association for 
the Study of Lung Cancer asked the Tobacco Control and Smoking 
Cessation Committee to formulate a statement on the use of e-cig-
arettes by cancer patients to help guide clinical practice. Below is 
this statement, which we will update periodically as new evidence 
becomes available.
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Tobacco consumption is the second leading cause of death in the world today, currently responsible for more than 5 
million deaths each year with many of these deaths occurring 
prematurely.1,2 Although there exists a wide diversity in the 
tobacco products available to consumers, ranging from cigars, 
pipes, and cigarettes to noncombustible forms of tobacco 
such a chewing tobacco and moist snuff, manufactured ciga-
rettes are by far the most common type of tobacco product 
consumed and also the most dangerous.3 Both combustible 
and noncombustible tobacco products pose health risks to 
the user, but cigarettes and combustible tobacco products are 
particularly dangerous with more than 6000 known chemical 
constituents and 60 known carcinogens and inherent design 
features that allow for deep inhalation of smoke and nicotine 
into the lungs.4 As a result, most people develop a strong 
 long-lasting addiction to cigarettes, which makes it hard to 
avoid the repeated exposures to harmful smoke toxins.5
The adverse effects of smoking continue after a can-
cer diagnosis. Continued smoking increases the risk for 
 treatment-related complications, recurrence, the develop-
ment of a second primary cancer, and mortality from both 
 cancer-related and non–cancer-related causes.4,6–11 The adverse 
effects of smoking are noted across cancer disease sites and 
affect treatment outcomes for surgery, chemotherapy, radio-
therapy, and targeted therapy such as biological therapies. 
Several studies have demonstrated that smoking cessation at 
or following a cancer diagnosis can reverse the adverse effects 
of tobacco on cancer treatment outcomes.12–15
Obviously, the best preventative measure to curb the 
adverse health effects associated with smoking is abstaining 
from smoking or tobacco cessation. Treatment-related guide-
lines are available to provide a foundation upon which to base 
smoking cessation intervention. However, the reality of help-
ing patients overcome their nicotine dependence is not as sim-
ple as telling someone to quit and offering a prescription for a 
stop smoking medication.16
Most cancer patients who persist in smoking already 
recognize the adverse health effects and the importance of 
stopping smoking. The vast majority of patients will report 
that they want to quit and have tried to stop previously, with 
many having used a range of methods from cold turkey to 
various forms of pharmacotherapy and behavioral support.17–19 
Because of the treatment-related consequences of continued 
smoking, there is urgency for most cancer patients to stop 
smoking immediately, yet tobacco cessation studies have 
often ignored cancer patients.20–22 Most cancer patients expect 
to be asked about their tobacco use when seen by their doc-
tor and are generally receptive to the offer of cessation sup-
port.23 Some patients are embarrassed by their smoking and 
will sometimes misrepresent their tobacco use, so biochemi-
cal markers such as cotinine and/or carbon monoxide can 
be used to help ensure more accurate assessment of current 
tobacco use.24 Although most oncologists seem to ask about 
tobacco use and advise patients to stop smoking, most do not 
regularly provide cessation assistance.21,22 However, assessing 
and assisting patients who use tobacco should be standard of 
care for all cancer patients.16,25 That said, clinicians are now 
faced with a new dilemma—what do we tell our patients about 
 e-cigarettes? What are e-cigarettes? Can e-cigarettes help 
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someone stop smoking? Are e-cigarettes less harmful than 
cigarettes?
WHAT ARE E-CIGARETTES?
Electronic cigarettes (i.e., e-cigarettes) are 
 battery-powered devices that delivery nicotine in an aerosol 
to the user.26–39 The first electronic cigarette was created in 
1963 when an American engineer named Herbert A. Gilbert 
filed a patent for a device that produced a nicotine-contain-
ing steam.40 However, this device was never commercial-
ized. The modern electronic cigarette was invented in 2003 
by a Chinese pharmacist named Hon Lik for his father who 
was a heavy smoker with lung cancer.41 E-cigarettes were 
sold first in China in 2004 and later exported by the ruyan 
company and made available over the Internet and more 
recently in retail establishments in Europe and in the United 
States. E-cigarettes heat and vaporize a solution containing 
nicotine, and many are designed to look outwardly like tradi-
tional tobacco cigarettes (Figure 1). Thus, as a cigarette-like 
device that mimics both hand-to-mouth and oral-sensory 
experiences of a traditional cigarette, e-cigarettes have the 
potential to attract significant numbers of customers who 
might otherwise smoke cigarettes.
CAN E-CIGARETTES HELP SOMEONE  
STOP SMOKING?
There are no clinical guidelines that recommend the 
use of e-cigarettes for smoking cessation. Electronic ciga-
rettes have not been approved as a stop smoking treatment by 
the U.S. Food and Drug Administration or any other govern-
ment agency responsible for evaluating the safety and efficacy 
of drugs for smoking cessation. Australia and Canada have 
banned the retail sale of e-cigarettes. Other countries, such as 
the United Kingdom, are considering regulating e-cigarettes 
like medicinal nicotine products. Although many smokers 
report using e-cigarettes to reduce or help them stop smoking, 
there is a paucity of reliable data on their efficacy for smoking 
cessation.33–39 Although a recent study found that e-cigarettes 
with or without nicotine were about as effective as a nicotine 
patch in helping smokers abstain from using tobacco ciga-
rettes,39 there are no published studies evaluating the safety and 
efficacy of e-cigarettes for smoking cessation in patients with 
chronic obstructive pulmonary disease (COPD) or cancer.
ARE E-CIGARETTES LESS HARMFUL  
THAN CIGARETTES?
E-cigarettes deliver heated nicotine aerosol with a few 
other chemicals, so compared with smoking cigarettes there 
is exposure to many fewer inhaled chemicals.31 For patients 
with a serious lung ailment, it is reasonable to be cautious 
about recommending the use of any treatment that involves 
inhaling foreign material into the airways. It is likely to be 
many years before the harms (if any) associated with the acute 
and long-term exposure to e-cigarettes can be more com-
pletely ascertained.
WHAT DO I TELL MY PATIENTS?
First, tell your patients to stop smoking cigarettes imme-
diately. There needs to be an urgency to get cancer patients to 
stop smoking because the adverse effects of continued smoking 
can be immediate and severe.6–11 Second, tell your patients that 
you are willing to work with them to overcome their nicotine 
dependence. The treatment guidelines for tobacco dependence 
are a good starting point to identify evidence-based options 
for smoking cessation,16 although you can acknowledge that 
current treatment approaches for nicotine dependence are 
only minimally effective.42 Third, explain to your patient that 
the safety and effectiveness of e-cigarettes are not fully under-
stood, nor is there any evidence to suggest that e-cigarettes 
are safer or more effective than existing government-approved 
stopping smoking medications. Table 1 provides some clini-
cal scenarios and suggestions on when e-cigarettes might or 
might not be considered as an adjunct to established nicotine 
dependence treatments.
In summary, cancer patients deserve treatment guidance 
from their doctor. Those who smoke should be advised to stop 
smoking and informed of the evidence-based treatment meth-
ods that have been shown to increase cessation outcomes com-
pared to unassisted quitting. Most smokers believe that they 
ought to be able to quit on their own without assistance and 
are skeptical about the value of current treatment approaches 
for nicotine dependence.43 However, given the importance of 
smoking cessation for cancer patients, oncologists should be 
insistent in their efforts to assist their patients to stop smoking 
including considering combination therapies.25,44
There are currently no evidence-based guidelines 
to support the recommendation of e-cigarettes. Whereas 
 evidence-based cessation strategies should be used wher-
ever possible, clinicians should consider the strong need for 
cancer patients to stop smoking as soon as possible to pro-
mote the most effective outcomes of cancer therapy. In the 
absence of sufficient evidence that e-cigarettes are effective 
and safe for treating nicotine dependence in cancer patients, 
the International Association for the Study of Lung Cancer 
advises against recommending their use at this time. However, 
this recommendation may change if new data become avail-
able. The International Association for the Study of Lung 
Cancer does recommend that research be done to evaluate 
the safety and efficacy of e-cigarettes as a cessation treat-
ment in cancer patients to help guide clinical practice. For 
individual patients who are either using or planning to use 
e-cigarettes despite advice not to do so, they should be offered 
FIGURE 1.  Schematic of an e-cigarette. Source: 
http://www.electroniccigaretteweb.com/faq/.
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 evidence-based stop smoking treatments while monitoring for 
any adverse effect of e-cigarette use.
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TABLE 1.  Clinical Scenarios and Suggested Responses for Patients
Clinical Scenarios Suggested Response Comment
The patient has recently 
stopped smoking, 
using methods other 
than e-cigarettes
The patient should be congratulated on having stopped 
smoking cigarettes and monitored for relapse to 
smoking. If the patient is using pharmacotherapy, it 
is worthwhile to discuss how long the patient feels 
a need to use the medications and discuss options to 
wean off medication support
The patient should be told to avoid using any form of tobacco including 
e-cigarettes since this might trigger relapse back to smoking. Some 
patients do benefit from the use of stop smoking medications beyond 
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recommended as a cessation therapy
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that e-cigarettes have not been established to be an effective treatment 
for stop smoking. A preference for established treatments should be 
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support while monitoring for any adverse effect of e-cigarette use. If 
e-cigarette use does not eliminate smoking, it should be discontinued
The patient continues 
to smoke and is not 
interested in stopping
The patient should be encouraged to stop smoking 
cigarettes, using evidence-based methods at every 
opportunity. repeated assessments, advice, and 
providing access to nicotine medications even for 
patients not ready to quit has been found to increase 
quit attempts and cessation
There is no evidence to support e-cigarette use in this scenario. research 
is needed in this area to define the actual benefits and harm associated 
with dual use of e-cigarettes and smoking
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